Teva links with Kowa to enter Japanese market
This article was originally published in Scrip
Teva Pharmaceutical Industrieshas struck an alliance with Kowa to set up an equally owned joint venture in Japan, which is to develop and market a range of generic products with a focus on those from the Israeli company's portfolio.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.